[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE3780814D1 - Verwendung von nukleosiden zur herstellung eines medikamentes zur behandlung von krankheiten, die durch einen retrovirus oder den hepatitis-b-virus verursacht werden. - Google Patents

Verwendung von nukleosiden zur herstellung eines medikamentes zur behandlung von krankheiten, die durch einen retrovirus oder den hepatitis-b-virus verursacht werden.

Info

Publication number
DE3780814D1
DE3780814D1 DE8888900484T DE3780814T DE3780814D1 DE 3780814 D1 DE3780814 D1 DE 3780814D1 DE 8888900484 T DE8888900484 T DE 8888900484T DE 3780814 T DE3780814 T DE 3780814T DE 3780814 D1 DE3780814 D1 DE 3780814D1
Authority
DE
Germany
Prior art keywords
carbon atoms
retrovirus
hepatitis
virus
nucleosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8888900484T
Other languages
English (en)
Other versions
DE3780814T2 (de
Inventor
Roelf Datema
Birgitta Gotthammar
Nils Johansson
Maria Kovacs
Gunnar Lindborg
Bertil Stening
Fredrik Oeberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivir AB
Original Assignee
Medivir AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir AB filed Critical Medivir AB
Application granted granted Critical
Publication of DE3780814D1 publication Critical patent/DE3780814D1/de
Publication of DE3780814T2 publication Critical patent/DE3780814T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE8888900484T 1986-12-19 1987-12-16 Verwendung von nukleosiden zur herstellung eines medikamentes zur behandlung von krankheiten, die durch einen retrovirus oder den hepatitis-b-virus verursacht werden. Expired - Lifetime DE3780814T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8605503A SE8605503D0 (sv) 1986-12-19 1986-12-19 Novel medicinal use
PCT/SE1987/000608 WO1988004662A1 (en) 1986-12-19 1987-12-16 Use of nucleosides for the manufacture of medicament for treatment of diseases caused by retrovirus or hepatitis b virus

Publications (2)

Publication Number Publication Date
DE3780814D1 true DE3780814D1 (de) 1992-09-03
DE3780814T2 DE3780814T2 (de) 1992-12-10

Family

ID=20366710

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8888900484T Expired - Lifetime DE3780814T2 (de) 1986-12-19 1987-12-16 Verwendung von nukleosiden zur herstellung eines medikamentes zur behandlung von krankheiten, die durch einen retrovirus oder den hepatitis-b-virus verursacht werden.

Country Status (9)

Country Link
EP (1) EP0294443B1 (de)
JP (1) JPH01501551A (de)
AT (1) ATE78824T1 (de)
AU (1) AU607965B2 (de)
CA (1) CA1306695C (de)
DE (1) DE3780814T2 (de)
DK (1) DK462688A (de)
SE (1) SE8605503D0 (de)
WO (1) WO1988004662A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989008115A1 (fr) * 1988-02-24 1989-09-08 Institut De Recherches Chimiques Et Biologiques Ap NOUVEAUX DERIVES DE LA DEOXY-2'-URIDINE SUBSTITUEE EN POSITION 5, 3' ou 5' PAR DES GROUPEMENTS alpha-AMINO ACYLES, PROCEDE POUR LEUR OBTENTION ET MEDICAMENTS LES CONTENANT
SE8802173D0 (sv) * 1988-06-10 1988-06-10 Astra Ab Pyrimidine derivatives
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
DD293498A5 (de) * 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
US6001840A (en) * 1990-03-06 1999-12-14 Southern Research Institute Methods of treatment of viral infections using carbocyclic deoxyguanosine analogs
GB9012899D0 (en) * 1990-06-09 1990-08-01 Wellcome Found Anti-hbv pyrimidine nucleoside
GB9125271D0 (en) * 1991-11-27 1992-01-29 Wellcome Found Anti-hbv pyrimidine nucleoside
ATE284894T1 (de) * 1994-10-24 2005-01-15 Genencor Int L-pyranosyl-nukleoside
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
WO2003018030A1 (en) * 2001-08-24 2003-03-06 Koronis Pharmaceuticals, Inc. Mutagenic nucleoside analogs for the treatment of viral disease
US7211570B2 (en) * 2001-12-20 2007-05-01 Pharmasset, Inc. Treatment of EBV and KHSV infection
WO2009113303A1 (ja) * 2008-03-12 2009-09-17 国立大学法人北陸先端科学技術大学院大学 光応答性プローブを用いたメチルシトシンの検出法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328388A (en) * 1964-09-02 1967-06-27 Merck & Co Inc Arabinofuranosyl pyrimidines and methods of preparing same
DE1620185C3 (de) * 1966-03-02 1982-01-14 Robugen Gmbh Pharmazeutische Fabrik Esslingen A.N., 7300 Esslingen 5-Äthyl- und 5-Propyl-2'-deoxyuridin, Verfahren zur Herstellung dieser Verbindungen und diese Verbindungen enthaltende Arzneimittel
AT281862B (de) * 1968-07-11 1970-06-10 Robugen Gmbh Verfahren zur Herstellung von neuen 2'-Desoxyuridinen
GB1601020A (en) * 1978-04-24 1981-10-21 Stichting Grega Vzw 2'-deoxy-5 (2-halogenovinyl)-uridines
US4247544A (en) * 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
US4267171A (en) * 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
JPS5639019A (en) * 1979-09-05 1981-04-14 Yamasa Shoyu Co Ltd Antiviral agent
GB2060604B (en) * 1979-10-03 1983-11-23 Univ Birmingham And Stichting E15-(2-halogenovinyl)-2'-deoxycytidines
JPS5687599A (en) * 1979-12-19 1981-07-16 Yamasa Shoyu Co Ltd E 55 22halogenovinyl arabinofuranosyluracil and its preparation
DE3045375A1 (de) * 1980-12-02 1982-07-01 Robugen Gmbh Pharmazeutische Fabrik Esslingen A.N., 7300 Esslingen Neue substituierte pyrimidin-nukleoside mit antiviraler wirkung, verfahren zu deren herstellung und daraus zubereitete arzneiformen
FR2531962B1 (fr) * 1982-08-17 1986-11-14 Sandoz Sa Nouveaux derives de la desoxyuridine, leur preparation et leur utilisation comme medicaments
JPS5979658A (ja) * 1982-10-28 1984-05-08 Fujitsu Ltd 複合交換機
IE56503B1 (en) * 1985-03-16 1991-08-14 Wellcome Found Antiviral nucleosides
AU7120987A (en) * 1986-02-20 1987-09-09 Sheldon B. Greer Composition for and method of treating aids and certain related diseases

Also Published As

Publication number Publication date
DE3780814T2 (de) 1992-12-10
CA1306695C (en) 1992-08-25
DK462688D0 (da) 1988-08-18
WO1988004662A1 (en) 1988-06-30
EP0294443A1 (de) 1988-12-14
EP0294443B1 (de) 1992-07-29
AU607965B2 (en) 1991-03-21
DK462688A (da) 1988-08-18
ATE78824T1 (de) 1992-08-15
JPH01501551A (ja) 1989-06-01
AU1083488A (en) 1988-07-15
SE8605503D0 (sv) 1986-12-19

Similar Documents

Publication Publication Date Title
DE3855099D1 (de) Nucleoside zur Verwendung für die Therapie
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
DE3780814D1 (de) Verwendung von nukleosiden zur herstellung eines medikamentes zur behandlung von krankheiten, die durch einen retrovirus oder den hepatitis-b-virus verursacht werden.
ATE135577T1 (de) Verwendung von buspiron zur herstellung eines pharmazeutischen präparats zur behandlung der alkoholsucht
CS689887A3 (en) Novel psychostimulating substances of the phenylalkylamine derivativestype, process of their preparation and pharmaceuticals comprising them
ATE257378T1 (de) Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen
DE3174807D1 (en) Pharmaceutical composition
KR890001580A (ko) B형 간염 바이러스에 의해 유발되는 염증 질환을 치료하는 이중가닥 rna를 함유하는 약물
DE69326395D1 (de) Spirooxathiolan-quinuclidin-Derivat zur Behandlung des Sjögren-Syndroms
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
ATE135914T1 (de) Aica riboside zur prophylaktischen behandlung von krankheiten mit einer verminderten durchblutung.
ATE125709T1 (de) Verwendung von ifn-gamma zur herstellung einer pharmazeutischen zusammensetzung für die behandlung von atl.
SE9003887L (sv) Cellproliferationsmatris och anvaendning daerav
KR950701638A (ko) 푸린 동족체의 항비루스성 포스폰산 유도체(Antiviral phosphonic acid derivatives of purine analogues)
DE69516110D1 (de) Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
MY104521A (en) Treatment of depression.
IT1245717B (it) Composto farmaceutico a base di un antocianidina per il trattamento di malattie oftalmiche
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
GR3001793T3 (en) Polyprenyl alcohol-containing injections and use thereof
DE3873188D1 (de) Verwendung von nigerizin zur herstellung eines mittels zur behandlung von virus-erkrankungen.
DE68916651D1 (de) Heilmittel zur behandlung von toxoplasmose.
ATE24834T1 (de) Verwendung von beta-(1-adamantyl)-alpha, alphadimethylethylamin zur herstellung eines arzneimittels zur behandlung von otitis externa bei hunden.
KR890017363A (ko) 스트로빌루린 유도체, 이들의 제법 및 용도

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee